Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Interest Receivables Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

SAB Biotherapeutics (SABS) Amortization of Deferred Charges (2021 - 2022)

SAB Biotherapeutics filings provide 2 years of Amortization of Deferred Charges readings, the most recent being $24717.0 for Q3 2022.

On a quarterly basis, Amortization of Deferred Charges fell 40.09% to $24717.0 in Q3 2022 year-over-year; TTM through Sep 2022 was $138939.0, a N/A change, with the full-year FY2021 number at $164983.0, changed 0.03% from a year prior.
Amortization of Deferred Charges hit $24717.0 in Q3 2022 for SAB Biotherapeutics, down from $31809.0 in the prior quarter.
In the past five years, Amortization of Deferred Charges ranged from a high of $41259.0 in Q1 2021 to a low of $24717.0 in Q3 2022.